Clinical Trials Logo
  1. Home
  2. Trauma
  3. NCT00123591
  4. Details
NCT00123591 Clinical Trial

Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury

Trauma Clinical Trial

Official title:
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/NiaStase®) in Subjects With Brain Contusions

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00123591
Other study ID # F7CBI-1600
Secondary ID 2004-000088-92
Status Completed
Phase Phase 2
First received June 30, 2005
Last updated January 11, 2017
Start date January 2005
Est. completion date May 2006

Study information
Verified date January 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority Taiwan: Department of HealthSpain: Spanish Agency of MedicinesSingapore: Health Sciences AuthorityCanada: Health CanadaFinland: Finnish Medicines AgencyItaly: Ministry of HealthGermany: Paul-Ehrlich-InstitutIsrael: Israeli Health Ministry Pharmaceutical AdministrationSwitzerland: SwissmedicIndia: Ministry of Health
Study type Interventional

Clinical Trial Summary

This trial is conducted in Asia, Europe, Middle East, and North America. The primary objective of the trial is to evaluate the safety of Recombinant Activated Factor VII in patients with brain contusions. The secondary objective of the trial is to evaluate the preliminary efficacy of Recombinant Activated Factor VII in preventing early haemorrhagic progression in contusive brain injury.

Recruitment information / eligibility
Status Completed
Enrollment 96
Est. completion date May 2006
Est. primary completion date May 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Contusive brain injury (including brain stem) diagnosed by history, clinical examination and confirmed by CT scan within 6 hours of onset

- In British Columbia and Nova Scotia, subjects must be = 19 years.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• activated recombinant human factor VII

Locations
Country Name City State
Canada Novo Nordisk Investigational Site Montreal
Finland Novo Nordisk Investigational Site Helsinki
Germany Novo Nordisk Investigational Site Hannover
India Novo Nordisk Investigational Site Bangalore
India Novo Nordisk Investigational Site New Dehli New Delhi
Israel Novo Nordisk Investigational Site Haifa
Israel Novo Nordisk Investigational Site Ramat Gan
Israel Novo Nordisk Investigational Site Tel-Aviv
Italy Novo Nordisk Investigational Site Cesena
Netherlands Novo Nordisk Investigational Site Rotterdam
Singapore Novo Nordisk Investigational Site Singapore
Singapore Novo Nordisk Investigational Site Singapore
Spain Novo Nordisk Investigational Site Barcelona
Switzerland Novo Nordisk Investigational Site Zürich
Taiwan Novo Nordisk Investigational Site Taoyuan

Sponsors (1)
Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Canada,  Finland,  Germany,  India,  Israel,  Italy,  Netherlands,  Singapore,  Spain,  Switzerland,  Taiwan, 

References & Publications (1)

Narayan RK, Maas AI, Marshall LF, Servadei F, Skolnick BE, Tillinger MN; rFVIIa Traumatic ICH Study Group.. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery. 2008 Apr;62(4):776-86; di — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Evaluate the Safety of Recombinant Activated Factor VII in Subjects with Brain Contusions Within the first 15 days of injury No
Secondary Evaluate the preliminary efficacy of Recombinant Activated Factor VII in preventing haemorrhagic progression in brain contusions No
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Terminated NCT03781817 - Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures Phase 4
Completed NCT04342416 - Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women N/A
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Recruiting NCT04725721 - Testing FIRST in Youth Outpatient Psychotherapy N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT03696563 - FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS N/A
Withdrawn NCT03249129 - Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Completed NCT02240732 - Surgical Tourniquets and Cerebral Emboli N/A
Completed NCT02227979 - Effects of PURPLE Cry Intervention N/A
Withdrawn NCT01169025 - Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT03112304 - Child STEPS for Youth Mental Health in Maine Sustainability N/A
Completed NCT01475344 - Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) Phase 1/Phase 2
Completed NCT01201863 - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Phase 4
Completed NCT01210417 - Trauma Heart to Arm Time N/A

External Links